Ferring’s heat-stable carbetocin could save thousands of women’s lives by preventing excessive bleeding after childbirth

Saint-Prex, Switzerland

Ferring Pharmaceuticals announced new data demonstrating that its heat-stable formulation of carbetocin is as effective as the current standard of care, oxytocin, for the prevention of excessive bleeding, also known as postpartum haemorrhage (PPH),after vaginal birth.

MagForce enrols first patient in NanoTherm Therapy study

Berlin, Germany & Nevada, USA

MagForce AG, a leading medical device company in the field of nanomedicine focused on oncology, together with its subsidiary MagForce USA, Inc. has announced MagForce USA has enrolled the first patient

I-Mab raises US$ 220 million to advance clinical development of a number of first-in-class assets


I-Mab Biopharma, a company focusing on innovative Biologics in therapeutic areas of immuno-oncology and immuno-inflammation, announced the completion of Series C financing for US$ 220 million

InflaRx gets IND approval from US FDA to start phase II trial of IFX-1 in ANCA associated vasculitis

Jena, Germany

InflaRx N.V., a biopharmaceutical company developing innovative therapeutics to treat life-threatening inflammatory diseases by targeting the complement system, a key component of the innate immune system

Noxxon updates on patient recruitment in ongoing NOX-A12 pancreatic and colorectal cancer clinical trial

Berlin, Germany

Noxxon Pharma N.V., a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced that patient recruitment is almost complete in its ongoing clinical trial

Industry leaders launch Next Phase Clinical Research

Our Bureau, Mumbai

Industry leaders Dr. Rhonda Paz, PhD, and Shirley Trainor-Thomas have launched Next Phase Clinical Research, which is a client-centric company focused on research infrastructure development for operational and

Cel-Sci wins breach of contract ruling against Syneos Health


After a four and a half year battle, a decision has been delivered by the arbitrator in Cel-Sci Corporation's arbitration suit against clinical development giant inVentiv, now part of Syneos Health. The arbitrator

Mallinckrodt completes enrollment of phase 4 trial of HP Acthar Gel for Rheumatoid Arthritis

Staines-upon-thames, UK

Mallinckrodt plc, a leading global specialty pharmaceutical company, announced it has completed enrollment of the company's ongoing Phase 4 clinical trial of HP Acthar Gel for Rheumatoid Arthritis (RA) patients.

Medivir's MIV-711 osteoarthritis phase IIa clinical study meets primary endpoint


Medivir AB has announced positive top-line results from the MIV-711 phase IIa extension study (MIV-711-202). The study met the primary endpoint, demonstrating that MIV-711 200mg had an acceptable safety

Biohaven to present data from pivotal phase 3 clinical trials of Rimegepant at AHS Annual Scientific Meeting 2018

New Haven, Conn

Biohaven Pharmaceutical Holding Company Ltd. is presenting expanded data from two randomized, pivotal Phase 3 clinical trials of rimegepant, Biohaven's small molecule calcitonin gene-related peptide (CGRP)


Enquiry Form